Non-eroding drug-releasing implants with ordered nanoporous and nanotubular structures: concepts for controlling drug release.

Biomater Sci

School of Chemical Engineering, The University of Adelaide, Engineering North Building, SA 5005, Adelaide, Australia.

Published: January 2014

To address the limitations of systemic drug delivery, localized drug delivery systems (LDDS) based on nano-engineered drug-releasing implants are recognized as a promising alternative. Nanoporous anodic alumina (NAA) and nanotubular titania (TNT) fabricated by a simple, self-ordering electrochemical process, with regard to their outstanding properties, have emerged as one of the most reliable contenders for these applications. This review highlights the development of new LDDS based on NAA and TNT, focusing on a series of strategies for controlling their drug release characteristics that are based on: modification of their nanopore/nanotube structures, altering internal chemical functionalities, controlling pore openings by biopolymer coatings and using polymeric micelles as drug nano-carriers loaded within the implants. Several new strategies on externally triggered stimuli-responsive drug release for LDDS are also reviewed, and their significance toward the development of advanced smart implants for localized therapy is discussed. Finally, the review is summarized with conclusions and future prospects in this research field.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c3bm60196jDOI Listing

Publication Analysis

Top Keywords

drug release
12
drug-releasing implants
8
controlling drug
8
drug delivery
8
ldds based
8
drug
6
non-eroding drug-releasing
4
implants
4
implants ordered
4
ordered nanoporous
4

Similar Publications

Mesoporous Silica with Dual Stimuli-Microenvironment Responsiveness via the Pectin-Gated Strategy for Controlled Release of Rosmarinic Acid.

ACS Appl Bio Mater

January 2025

College of Chemical and Biological Engineering, Zhejiang Provincial Key Laboratory of Advanced Chemical Engineering Manufacture Technology, Zhejiang University, Hangzhou 310027, China.

Traditional drug-delivery methods are limited by low bioavailability and nonspecific drug distribution, resulting in poor therapeutic efficacy and potential risks of toxicity. Mesoporous silica nanoparticles (MSNs) have attracted wide attention as drug-delivery carriers due to their large specific surface area, adjustable pore size, good mechanical strength, good biocompatibility, and rich hydroxyl groups on their surface. In this paper, MSNs were synthesized by a template method, and the morphology and pore structure were regulated.

View Article and Find Full Text PDF

A Granzyme B-Cleavable T Cell-Targeted Bispecific Cell Vesicle Connector for Reversing New-Onset Type 1 Diabetes.

J Am Chem Soc

January 2025

State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Type 1 diabetes (T1D) is an autoimmune disorder in which pancreatic β-cells are destroyed by CD8 T cells. Anti-CD3 antibody effectively treats early-stage T1D when β-cell autoantibodies are detected but before symptoms appear. However, it impairs the immune system temporarily, exposing individuals to infection.

View Article and Find Full Text PDF

Cholesterol-terminated cationic lipidated oligomers (CLOs) as a new class of antifungals.

J Mater Chem B

January 2025

Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC, 3052, Australia.

Infections caused by fungal pathogens are a global health problem, and have created an urgent need for new antimicrobial strategies. This report details the synthesis of lipidated 2-vinyl-4,4-dimethyl-5-oxazolone (VDM) oligomers an optimized Cu(0)-mediated reversible-deactivation radical polymerization (RDRP) approach. Cholesterol-Br was used as an initiator to synthesize a library of oligo-VDM (degree of polymerisation = 5, 10, 15, 20, and 25), with an α-terminal cholesterol group.

View Article and Find Full Text PDF

Design of ROS-Triggered Sesquiterpene Lactone SC Prodrugs as TrxR1 Covalent Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

J Med Chem

January 2025

Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province; Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province; Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.

Thioredoxin reductase 1 (TrxR1) is an important therapeutic target for nonsmall cell lung cancer (NSCLC) treatment due to its overexpression in NSCLC cells. In this work, to address the deficiency that sesquiterpene lactone containing α-methylene-γ-lactone moiety was rapidly metabolized by endogenous nucleophiles, series of novel thioether derivatives were designed and synthesized based on a reactive oxygen species (ROS)-triggered prodrug strategy. Among them, prodrug exhibited potent cytotoxicity against NSCLC cells and better release rates in response to ROS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!